Krystal Biotech to Present at TD Cowen 46th Annual Health Care Conference

Company Overview - Krystal Biotech, Inc. is a fully integrated, commercial-stage global biotechnology company focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs [3] - The company's first commercial product, VYJUVEK, is the first-ever redosable gene therapy and the first genetic medicine approved in the United States, Europe, and Japan for the treatment of dystrophic epidermolysis bullosa [3] - Krystal Biotech is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines [3] Upcoming Events - The company will participate in the TD Cowen 46th Annual Health Care Conference on March 3, 2026, in Boston [1] - Company executives will take part in a fireside chat scheduled at 3:10 pm ET and host investor meetings throughout the day [1] - A webcast of the presentation will be available starting at 3:10 pm ET on March 3, 2026, and will be posted on the Investors section of the company's website [2]